Updated:
Nextel Medical
Nextel Medical, founded by Dr. T. Wade Fallin, developed the Bunionplasty Procedure before its 2021 acquisition by Zimmer Biomet.
Nextel Medical
Founded by podiatric surgeon Dr. T. Wade Fallin, Nextel Medical operated as a privately held orthopedic device company focused exclusively on forefoot reconstruction. Dr. Fallin, a practicing surgeon, designed the proprietary Nextra system to address hammertoe and later adapted the intramedullary implant concept for hallux valgus correction. The Bunionplasty Procedure launched as an alternative to first-metatarsal osteotomy, using a two-piece, fully threaded titanium implant delivered through a single small incision. The device offered surgeons a technique that preserved bone stock and allowed immediate weight-bearing, a meaningful departure from conventional screw-and-plate constructs. The company's product line remained tightly scoped to two primary indications: hammertoe and bunion correction. Unlike diversified orthopedic platforms, Nextel Medical did not pursue hip, knee, or trauma markets. Its commercial model relied on surgeon-training programs and direct sales representation concentrated in the United States. Zimmer Biomet's 2021 acquisition did not disclose financial terms, but the deal included both the Nextra and Bunionplasty systems — suggesting a focused asset sale rather than an enterprise acquisition. Zimmer Biomet integrated the implants into its existing foot-and-ankle portfolio, leveraging its established distribution network. The company maintained a lean operational structure. Dr. Fallin served as both founder and lead inventor, holding multiple patents on the implant geometry and insertion instrumentation. The firm's physical footprint and total employee count were never publicly documented, consistent with a development-stage device company that outsourced manufacturing and scaled through strategic partnerships. No known venture capital rounds were disclosed; the company appears to have been funded through surgeon-founder equity and early commercial revenue. Nextel Medical's structural profile reflects the classic single-surgeon-innovator device pathway: a practicing clinician identifies an unmet procedural need, designs the implant and instruments, secures regulatory clearance, builds a narrow commercial footprint, and exits to a strategic acquirer. That pattern — inventor-surgeon to strategic exit without institutional capital — distinguishes it from venture-backed device startups that raise Series A rounds before 510(k) submission. The Zimmer Biomet acquisition validated the implant's clinical utility but left no ongoing independent entity.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
—
Sector focus
Frequently asked questions
What was the core clinical problem Nextel Medical's technology solved?
Traditional bunion surgery — first-metatarsal osteotomy — requires cutting and repositioning bone, followed by a non-weight-bearing recovery period. Nextel Medical's Bunionplasty Procedure used an extra-articular implant that stabilized the first metatarsophalangeal joint without osteotomy. The technique allowed immediate weight-bearing post-surgery and preserved bone stock for any future revision procedures.
Who founded Nextel Medical and what was their background?
Podiatric surgeon Dr. T. Wade Fallin founded the company and invented the Nextra implant system. He practiced clinically while designing the device, a pattern common among orthopedic surgeon-entrepreneurs. Dr. Fallin held patents on both the implant geometry and the specialized instrumentation used for insertion.
How did the Zimmer Biomet acquisition affect the product line?
Zimmer Biomet acquired the Nextra Hammertoe Correction System and the Bunionplasty Procedure as a package in 2021. The implants were folded into Zimmer Biomet's existing foot-and-ankle franchise, which includes competing and complementary fixation systems. The Nextra brand was preserved briefly post-acquisition before being integrated under Zimmer Biomet's product naming conventions.
What regulatory clearances did Nextel Medical obtain?
The FDA cleared the Nextra Hammertoe Correction System via the 510(k) pathway, a standard requirement for Class II orthopedic implants. The Bunionplasty Procedure later received separate 510(k) clearance as a new indication for the implant platform. No PMA (premarket approval) pathway was required, consistent with the device's risk classification as a non-life-sustaining implant.
Was Nextel Medical venture-backed?
No publicly disclosed venture capital rounds exist. The firm likely operated on surgeon-founder equity and early commercial revenue, a common structure among single-surgeon device companies that avoid institutional dilution. The lean model — outsourced manufacturing, narrow product scope, direct sales — reduced capital requirements ahead of the strategic exit to Zimmer Biomet.
What makes the Bunionplasty implant structurally different from traditional plates and screws?
The implant is a two-piece, fully threaded titanium construct that sits within the intramedullary canal of the first metatarsal and proximal phalanx. Unlike dorsal plates or crossing screws, it does not require periosteal stripping or bone cutting. That preserves vascular supply and eliminates the risk of hardware prominence, a common complaint with traditional dorsal plate fixation.
Does Nextel Medical still operate independently?
No. Following the 2021 asset sale, the company ceased independent operations. The intellectual property, inventory, and regulatory clearances transferred to Zimmer Biomet. Dr. Fallin's ongoing role, if any, within Zimmer Biomet after the acquisition was not publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: